Peer-influenced content. Sources you trust. No registration required. This is HCN.
Annals of Internal Medicine
Although genomic classifier tests for prostate cancer show promise, a systematic review of 22 studies reveals marked differences between observational and trial data in how these tests influence risk stratification and treatment selection.
Oncology, Medical February 3rd 2025
Dana-Farber Cancer Institute
Latest clinical trial data suggests active monitoring may be a viable alternative to standard treatment for select low-risk DCIS patients, with comparable quality-of-life outcomes.
Oncology, Medical January 21st 2025
Practical Neurology
The multidisciplinary guidelines introduce blood-based biomarkers as key diagnostic tools, potentially reducing unnecessary CT scans while improving outcome predictions.
Emergency Medicine January 8th 2025
Mayo Clinic Labs
Poor metabolizers of UGT1A1 face a significantly increased risk of severe neutropenia from irinotecan therapy, making genetic testing crucial for appropriate dose modification.
Clinical Pharmacology December 3rd 2024
Cancer Therapy Advisor
AI-assisted diagnosis of lung cancer showed 87% sensitivity and 87% specificity in a meta-analysis, suggesting potential for improved accuracy in interpreting chest CT scans.
Oncology, Medical October 8th 2024
The I-SPY2 trial demonstrates that novel treatment approaches can yield high pathologic complete response rates in rare histologic subtypes of high-risk breast cancer, potentially improving outcomes for these challenging cases.
Oncology, Medical August 26th 2024